stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Return on invested capital
LivaNova PLC's return on invested capital over the twelve months to 30 September 2026 was 9.14%, down 4.1 percentage points from fiscal 2025 (13.2%). Over the past ten years it has ranged from −11.3% (fiscal 2020) to 44.2% (fiscal 2015); the current reading is higher than 92% of that period. That is above the Medical Devices industry median of −5.27% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 13.2% | 6.65 |
| FY2024 | 6.59% | 9.92 |
| FY2023 | −3.33% | 0.56 |
| FY2022 | −3.89% | (3.85) |
| FY2021 | −0.04% | 11.28 |
| FY2020 | −11.3% | (4.86) |
| FY2019 | −6.46% | 3.08 |
| FY2018 | −9.54% | (12.77) |
| FY2017 | 3.23% | 2.06 |
| FY2016 | 1.17% | 1.17 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LIVN LivaNova PLC | 9.14% |
| HAE Haemonetics Corporation compare | 6.31% |
| ITGR Integer Holdings Corporation compare | 3.16% |
| NEOG Neogen Corporation compare | −0.17% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| AXGN AxoGen, Inc. compare | −5.27% |
| IRTC iRhythm Holdings, Inc. compare | −11.4% |
| TXG 10x Genomics compare | −20.2% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement